Coronary heart disease (CHD). Early research suggests that injecting 500 mL of puerarin, a chemical in kudzu and usually extracted from it, intravenously (by IV) once daily for 3 weeks might reduce “bad” low-density lipoprotein (LDL) cholesterol, increase “good” high-density lipoprotein (HDL) cholesterol, and reduce pre-meal insulin levels in people with coronary heart disease. Puerarin injection products are not available in North America.

Diabetes. Early research suggests that taking puerarin, a chemical in kudzu(kudzu root extract), 750 mg daily by mouth along with the diabetes medication rosiglitazone (Avandia) reduces blood sugar in patients with type 2 diabetes. However, injecting puerarin intravenously (by IV) does not appear to reduce blood sugar. Puerarin injection products are not available in North America.

Kidney disease in people with diabetes (diabetic nephropathy). Early research suggests that taking puerarin, a chemical in kudzu(kudzu root extract), 750 mg daily by mouth along with the diabetes medication rosiglitazone (Avandia) improves kidney function in people with diabetic nephropathy.

Problems with the retina of the eye in people with diabetes (diabetic retinopathy). Some research suggests that injecting puerarin, a chemical in kudzu(kudzu root extract), intravenously (by IV) does not improve vision in people with diabetic retinopathy. Puerarin injection products are not available in North America.

However,more evidence is needed to rate the effectiveness of kudzu for these uses.

#KudzuRootExtract #Puerarin